Press releases
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development
ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
News and events
With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’ | BioPharma Dive
Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma | Endpoints News
Publications and presentations
Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | bioRxiv
ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference